significantTreatment update
IL-1 blockade established as standard second-line therapy for colchicine-resistant FMF
Familial Mediterranean Fever →Summary
Meta-analysis by Grattagliano et al. (2023) and updated EULAR/PReS 2024 recommendations confirm anti-IL-1 agents (anakinra, canakinumab) significantly reduce attack frequency and inflammatory markers in colchicine-resistant FMF. Both anakinra and canakinumab show high efficacy with complete response rates of 67-77%.
Related treatments
More from Familial Mediterranean Fever
significantTreatment update
JAK inhibitors (tofacitinib) emerging as potential third-line therapy
significantTreatment update
EULAR/PReS 2024 updated management recommendations published
significantNew research
Colchicine resistance mechanisms linked to pyrin inflammasome microtubule independence
incrementalGenetic finding
SAA1 gene polymorphisms identified as independent amyloidosis risk modifier
ID: familial-mediterranean-fever-update-0Type: treatment_updateImpact: significant